Daewoong Pharma reports 104 patients enrolled in Phase 2 IPF trial of Bersiporocin
Bitget2026/09/24 07:01- Daewoong Pharma presented baseline data for 104 patients in a global Phase 2 trial of IPF candidate bersiporocin at ERS 2026.
- The study is designed to test the drug in patients already on standard antifibrotic therapy, as well as those not receiving it.
- Enrollment is complete in the US and South Korea, positioning the program for a key efficacy and safety readout.
- Top-line Phase 2 results are expected in H1 2027, a near-term catalyst for the asset’s next-stage development plans.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
